R Gama Landgraf1, S Jancar, A A Steil, P Sirois. 1. Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1730, 05508-900 São Paulo, Brazil.
Abstract
OBJECTIVE: The effect of bradykinin (B(1) or B(2)) receptor antagonists was studied in allergic and immune-complex-induced lung inflammation. METHODS: Lungs of BALB/c mice were examined 24 h after induction of lung inflammation, either allergic (ovalbumin-sensitized submitted to two aerosol of antigen, one week apart) or immune-complex induced (intratracheal instillation of IgG antibodies followed by intravenous antigen). The bradykinin B(2) receptor antagonist, HOE-140 or bradykinin B(1) receptor antagonist, R-954 were given intraperitoneally (100 microg/kg), 30 min before induction. RESULTS: In allergic inflammation, pre-treatment with R-954 reduced eosinophil infiltration into the lungs, mucus secretion and the airway hyperreactivity to methacholine. Pre-treatment with HOE-140 increased eosinophil infiltration but did not affect the other parameters. In immune-complex inflammation, HOE-140 increased neutrophil infiltration but not their activation nor the hemorrhagic lesions. R-594 pre-treatment did not change the parameters examined. CONCLUSION: These results show important modulatory effects of bradykinin B(1) and B(2) receptor antagonists in both models of lung inflammation.
OBJECTIVE: The effect of bradykinin (B(1) or B(2)) receptor antagonists was studied in allergic and immune-complex-induced lung inflammation. METHODS: Lungs of BALB/c mice were examined 24 h after induction of lung inflammation, either allergic (ovalbumin-sensitized submitted to two aerosol of antigen, one week apart) or immune-complex induced (intratracheal instillation of IgG antibodies followed by intravenous antigen). The bradykinin B(2) receptor antagonist, HOE-140 or bradykinin B(1) receptor antagonist, R-954 were given intraperitoneally (100 microg/kg), 30 min before induction. RESULTS: In allergic inflammation, pre-treatment with R-954 reduced eosinophil infiltration into the lungs, mucus secretion and the airway hyperreactivity to methacholine. Pre-treatment with HOE-140 increased eosinophil infiltration but did not affect the other parameters. In immune-complex inflammation, HOE-140 increased neutrophil infiltration but not their activation nor the hemorrhagic lesions. R-594 pre-treatment did not change the parameters examined. CONCLUSION: These results show important modulatory effects of bradykinin B(1) and B(2) receptor antagonists in both models of lung inflammation.
Authors: João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos Journal: Br J Pharmacol Date: 2004-11-01 Impact factor: 8.739
Authors: Elizabeth S Fernandes; Giselle F Passos; Maria M Campos; Glória E P de Souza; Juliana F Fittipaldi; Jorge L Pesquero; Mauro M Teixeira; João B Calixto Journal: Br J Pharmacol Date: 2005-09 Impact factor: 8.739
Authors: Jack Yang; Cornelis van 't Veer; Joris J T H Roelofs; Jeroen W J van Heijst; Alex F de Vos; Keith R McCrae; Alexey S Revenko; Jeff Crosby; Tom van der Poll Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-10-25 Impact factor: 5.464
Authors: Pamella H M Wang; Gabriela Campanholle; Marcos A Cenedeze; Carla Q Feitoza; Giselle M Gonçalves; Richardt G Landgraf; Sonia Jancar; João B Pesquero; Alvaro Pacheco-Silva; Niels O S Câmara Journal: PLoS One Date: 2008-08-25 Impact factor: 3.240